Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study

22 May 2023 (10:51 - 11:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Finn Gustafsson

Pleasanton (United States of America)

4 More presentations in this session

Presentation thumbnail

Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

Professor J. Inamo (Fort de France, MQ)

Abstract Slides Video

Presentation thumbnail

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

Professor N. Piriou (Nantes, FR)

Abstract Slides Video

Presentation thumbnail

Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

Doctor S. Selvaraj (Durham, US)

Abstract Slides Video

Presentation thumbnail

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Doctor A. Ioannou (Greater London, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiac amyloidosis from epidemiology to treatment

The Event

Event poster

Heart Failure 2023

22 May 2023 10:51 CET

You may be interested in

Congress Presentation

Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study

Congress Presentation

Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis

Congress Session

Cardiac amyloidosis from epidemiology to treatment

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources